MBXBF (Microbix Biosystems) Net Income (Continuing Operations): $-3.53 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBXBF Microbix Biosystems Inc MBXBF
54 GF Score
Price $0.22
GF Value $0.16
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Net Income (Continuing Operations)?

Microbix Biosystems MBXBF 54 Net Income (Continuing Operations) is $-3.53 Mil as of Jun. 2026. GuruFocus rates MBXBF with a GF Score™ of 54/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Microbix Biosystems's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-0.58 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.53 Mil.

Microbix Biosystems  (OTCPK:MBXBF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Microbix Biosystems Net Income (Continuing Operations) Related Terms

Microbix Biosystems Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems Net Income (Continuing Operations) Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 1.34 -0.03 2.60 -1.62

Microbix Biosystems Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -1.07 -0.85 -1.04 -0.58
MBXBF
54GF Score
Microbix Biosystems Inc MBXBF
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-3.53 Mil mean?
Microbix Biosystems (MBXBF) has a Net Income (Continuing Operations) of $-3.53 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Net Income (Continuing Operations) too high?
Microbix Biosystems' current Net Income (Continuing Operations) is $-3.53 Mil. Overall, Microbix Biosystems has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Net Income (Continuing Operations) compare to VRTX and REGN?
Microbix Biosystems' Net Income (Continuing Operations) of $-3.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Net Income (Continuing Operations) is $-3.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.22 — trading 35.8% above its estimated fair value. The current Net Income (Continuing Operations) is $-3.53 Mil. Microbix Biosystems' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Net Income (Continuing Operations) is $-3.53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (MBXBF) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of $0.22 is trading 35.8% above its estimated GF Value™ of $0.16. GuruFocus considers Microbix Biosystems to be Significantly Overvalued.

Key valuation signals for MBXBF:

  • Net Income (Continuing Operations): $-3.53 Mil
  • GF Value™: $0.16 vs. price of $0.22 (35.8% above fair value)
  • GF Score™: 54/100 with 8 warning signs

No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Other Exchanges MBX:Canada
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
54GF Score

Get the complete analysis for MBXBF

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price
$0.16
GF Value